June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
The Effect of Early Post-op Anti-Hypertensive Agents on the Hypertensive Phase following Ahmed FP 7 Glaucoma Valve Implantation, a Retrospective Review
Author Affiliations & Notes
  • Brenton Finklea
    Ophthalmology, University of Virginia, Charlottesville, VA
  • Ankur Gupta
    Ophthalmology, University of Virginia, Charlottesville, VA
  • Sandra Johnson
    Ophthalmology, University of Virginia, Charlottesville, VA
  • Footnotes
    Commercial Relationships Brenton Finklea, None; Ankur Gupta, None; Sandra Johnson, Merck (C), Aquesys (C), SOLX (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4776. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Brenton Finklea, Ankur Gupta, Sandra Johnson; The Effect of Early Post-op Anti-Hypertensive Agents on the Hypertensive Phase following Ahmed FP 7 Glaucoma Valve Implantation, a Retrospective Review. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4776. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: This study investigates the effects of the early implementation of glaucoma medications on the incidence and severity of the hypertensive phase, as well the effect on long term intraocular pressure (IOP) control in patients status post Ahmed glaucoma valve implantation.

Methods: This is a retrospective, non-comparative case series of Ahmed glaucoma implant surgeries performed at the University of Virginia, between September 2008 and January 2012. To date, 75 patients have met inclusion criteria, of which 63 completed a minimum of 90 days of follow up. Absolute IOP as well as percentage relative to pre-operative baseline were recorded. Patients are divided into two groups. The Conventional Treatment Group (CTG) (n=44) included patients in whom glaucoma medications were initiated at the onset of the hypertensive phase (IOP >21 mmHg in the first 8 weeks post-op). The Interventional Treatment Group (ITG) (n=19) are patients in whom glaucoma medications are initiated at IOP<21 mmHg.

Results: CTG and ITG were similar with respect to age and gender distribution. Preoperative average IOP was similar between the CTG and ITG (35.3 vs 33.1) though number of pre-op medications were fewer in the CTG (3.23 vs 4.11). At post-op month 3, the absolute IOP and percentage of baseline for the CTG and ITG were 16.81/54% and 18.85/61%, respectively. At post-op month 6, these indices for the CTG and ITG were 20.69/59% and 17.82/54%, respectively. Patients in the ITG were given more glaucoma medications than those in the CTG at post-op month 3 (2.38 vs 1.19). At 6 months, there was a smaller difference in medications between the ITG and CTG (2.29 vs 1.73). Overall, 31.6% of patients in the ITG experienced a hypertensive phase, compared with 64% of patients in the CTG.

Conclusions: In this sampling, a significantly lower percentage of the ITG experienced a hypertensive phase compared to the CTG. In addition, the 6 month IOP was lower in the ITG, suggesting a positive impact of early introduction of glaucoma medications postoperatively for Ahmed glaucoma valve implantation. The ITG did continue to require 0.56 more glaucoma medications than the CTG at 6 months, but this is a slight decrease from the preoperative difference of 0.88. Further statistical analysis will be presented, as well as data on patients in our study who continue to meet end points.

Keywords: 462 clinical (human) or epidemiologic studies: outcomes/complications • 464 clinical (human) or epidemiologic studies: risk factor assessment • 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×